RA: Klinik, Diagnostik und Outcome

RA: Klinik, Diagnostik und Outcome Update Rheumatologie ∙ RA: Klinik, Diagnostik und Outcome Keine erhöhte Malignomrate unter Biologika jahre). 287 dieser Patienten ent- Originalpublikation wickelten erstmals ein Melanom. Die standardisierten Inzidenzrati- Mercer LK, Askling J et al (2017) Risk of invasive melanoma in os (SIRs) waren für Biologika-nai- patients with rheumatoid arthritis ve Patienten 1,1 (95 %-CI 0,9–1,4), treated with biologics: results für TNF-Inhibitor-Behandelte 1,2 from a collaborative project of (0,99–1,6) und für Rituximab-ex- 11 European biologic registers. ponierte Patienten 1,3 (0,6–2,6). Ann Rheum Dis 76:386–391 Die Inzidenzrate verglichen mit Mercer LK, Galloway JB et al (2016) Biologika-naiven Patienten war Risk of lymphoma in patients exposed to antitumour necrosis für TNF-Inhibitoren 1,1 (95 %-CI factor therapy: results from the 0,8–1,6), für Rituximab 1,2 (0,5– British Society for Rheumatology 2,9). Die Schlussfolgerung war, 9 Eine anti- Biologics Register for Rheumatoid TNF-Therapie dass diese große europäische Ko- Arthritis. Ann Rheum Dis. ist offenbar operation keinen Hinweis auf ein http://dx.doi.org/10.1136/ nicht mit einem annrheumdis-2016-209389 erhöhtes Melanomrisiko nach Tumorrisiko Behandlung mit TNF-Inhibito- assoziiert Eine Arbeitsgruppe um Mer- ren fand. cer und Askling untersuchte un- Eine Auswertung des Regis- ter Auswertung von 11 Biologi- ters der britischen Gesellschaft für Gruppe 30 Lymphome (154 pro sehr erleichternd, dass nach aktu- ka-Registern aus 9 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Zeitschrift für Rheumatologie Springer Journals

RA: Klinik, Diagnostik und Outcome

Loading next page...
 
/lp/springer_journal/ra-klinik-diagnostik-und-outcome-5vNRDh904G
Publisher
Springer Medizin
Copyright
Copyright © 2017 by Springer Medizin Verlag GmbH
Subject
Medicine & Public Health; Internal Medicine; Rheumatology
ISSN
0340-1855
eISSN
1435-1250
D.O.I.
10.1007/s00393-017-0387-0
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial